|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.185 USD | -1.58% |
|
+4.85% | +20.00% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 178.9 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 23.56% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 178.9 | 178.9 | 178.9 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 23.56% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 11.4x | 44.4x | 222x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.6x | -2.8x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.28x | 2.65x | 2.65x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.28x | 2.65x | 2.65x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 10.2x | 60.3x | 724x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.195 | 0.05 | 0.01 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 78.3 | 67.56 | 67.46 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 17.52 | 2.968 | 0.247 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 15.72 | 4.074 | 0.731 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.220 | 2.220 | 2.220 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 31/3/22 | 27/2/23 | 14/3/24 | 17/3/25 | 18/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 11.38x | - | - | - | 179M | |
| 32.01x | 11.69x | 23.99x | 0.62% | 980B | |
| 24.41x | 5.63x | 15.32x | 2.34% | 550B | |
| 26.86x | 6.49x | 13.28x | 3.17% | 382B | |
| 17.04x | 4.24x | 10.43x | 3.13% | 316B | |
| 21.94x | 4.59x | 13.02x | 1.91% | 272B | |
| 20.28x | 5.27x | 12.78x | 3.05% | 268B | |
| 13x | 4.83x | 9.94x | 3.87% | 199B | |
| 21.95x | 5.91x | 10.33x | 2.99% | 182B | |
| -44.34x | 5.36x | 29.54x | 2.62% | 154B | |
| Average | 14.45x | 6.00x | 15.40x | 2.63% | 330.25B | |
| Weighted average by Cap. | 21.68x | 7.24x | 16.85x | 2.17% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
